Congress Materials - 2024 Psych Congress Elevate
2024 Psych Congress Elevate | May 30-Jun 2 | Las Vegas, NV
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
Clinical Effectiveness of Esketamine for Treatment-Resistant Depression: A Real-World Study of Patients in Mindful Health Solutions Clinics
Jennifer Guo, Maryia Zhdanava, Kruti Joshi, Aditi Shah, Dominic Pilon, Bronwyn Moore, Fengyi Jiang, Tobias Marton
Comparative Effectiveness of Oral and Long-Acting Injectable Antipsychotics in Schizophrenia: A Real-World Study in the US Medicare Population
Pengxiang Li, Zhi Geng, Carmela Benson, Charmi Patel, Jalpa A. Doshi
Earlier Use of Long-Acting Injectable Paliperidone Palmitate Versus Oral Antipsychotics in Patients With Schizophrenia: An Integrated Patient-Level Post Hoc Analysis of the PRIDE and PROSPIAL Studies
Martha Sajatovic, Oliver Lopena, Karen Johnston, Ibrahim Turkoz, Nia Josiah, Camilo Obando
How Patients With Depression and Their Providers Navigate Anhedonia: An Ethnographic Evaluation of Discourse Dynamics of Psychiatrists and Primary Care Providers in Clinical Settings
Tiina Drissen, Chelsea McCracken, Hrishikesh Kale, Zachary Hebert, Craig Chepke
Latent Variable Analysis of Antipsychotic Adherence Among South Carolina Medicaid Beneficiaries With Schizophrenia
Charmi Patel, Carmela Benson, Pujing Zhao, Ismaeel Yunusa, Chris Kozma, Gene Reeder, Chao Cai
Long-Term Efficacy of Esketamine Nasal Spray Among Early and Delayed Responders: A Subgroup Analysis of the SUSTAIN-3 Study
John Zajecka, Dong-Jing Fu, Naim Zaki, Ibrahim Turkoz, Patricia Cabrera, Oliver Lopena, Phung Quach, Sherry Fua
Long-Term Safety and Efficacy of Esketamine Nasal Spray by Dosing Frequency in Adults With Treatment-Resistant Depression: Analysis of the SUSTAIN-3 Study
John Zajecka, Dong-Jing Fu, Naim Zaki, Ibrahim Turkoz, Patricia Cabrera, Oliver Lopena, Manish Patel, Sherry Fua
Real-World Change in Depressive Symptoms Among Patients With Treatment-Resistant Depression Initiated on Esketamine Nasal Spray
Kristin Clemens, Maryia Zhdanava, Amanda Teeple, Arthur Voegel, Anabelle Tardif-Samson, Fengyi Jiang, Dominic Pilon, Kruti Joshi
Real-World Safety Profile of Esketamine Nasal Spray During the First 12 Treatment Sessions: An Analysis at 58 Months After Approval in the United States
Mai Himedan, Ibrahim Turkoz, Teodora Doherty, Brianne Brown, Phung Quach, David M. Kern, Gerard Sanacora
Risk of Relapse Among Medicare Advantage Members Diagnosed With Schizophrenia and Receiving Once-Monthly Paliperidone Palmitate or First-Generation Long-Acting Injectable Antipsychotics
Charmi Patel, Zhiwen Liu, Alicia K. Campbell, Carmela Benson
Treatment Patterns and Persistence Among Patients With Treatment-Resistant Depression Initiated on Esketamine Nasal Spray
Kristin Clemens, Maryia Zhdanava, Amanda Teeple, Arthur Voegel, Anabelle Tardif-Samson, Fengyi Jiang, Dominic Pilon, Kruti Joshi
Variables Associated With Remission in Patients Treated With Esketamine Nasal Spray or Quetiapine Extended-Release: A Post Hoc Subgroup Analysis of the ESCAPE-TRD Study
Greg Mattingly, Ibrahim Turkoz, Mai Himedan, Oliver Lopena, Lisa Lim, Manish Patel, Larry Martinez
Copies of these presentations are for personal use only and may not be reproduced without permission from the author of this presentation.